Here, we cover the so-called lympholytic immunosuppressants, namely polyclonal antilymphocyte antibodies, anti-CD3 monoclonal antibody (MAb), and anti-CD25 MAb. In particular, the use of lympholytics in the context of induction therapy in LT is emphasized with mention being made of reversal of...
Todd PA, Brogden RN (1989) Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37:871–899 Article CAS PubMed Google Scholar Emmons C, Hunsicker LG (1987) Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med 77:78–...
and mouse survival was analyzed. Results: PAS therapy increased expression of double negative T-cells. The percentage of gamma-delta T-cells in the (CD3+/CD4−/CD8−/CD44−/CD62L−) TEMRA subpopulation of mice treated with PAS or combinations of PAS with PD-1 Ab were ...
It is reasonable to assume that the antibody recruitment approach, or for that matter any immune-based cancer therapy, will not be curative as monotherapy. We, therefore, assessed whether combination with potentially complementary immune treatments could further augment VEGF–DNP-mediated tumor inhibition...
Three-dimensional microscopy reveals an activating hub composed of polarized CD3, CD28, and phosphatidylinositol 3-kinase (PI3K) activity at the putative immunological synapse with an inhibitory hub composed of polarized PD-1 and CD73 at the opposite pole of mitotic blasts. Progenitor T cells from ...
In particular, MDS patients had a mean frequency of CD3+ and CD16-56+ cells over total lymphocytes equal to 62% and 22%, respectively, while CD4+ and CD8+ subsets were 30% and 24%, respectively. Moreover, we showed that MDS patients had a higher frequency of CD4+CD25high Foxp3+ ...
Foxp3-TransducedPolyclonalRegulatoryTCellsProtect againstChronicRenalInjuryfromAdriamycin YuanMinWang,*GeoffYuZhang,*YipingWang, † MinHu,*HuilingWu,* DebbieWatson,*ShoheiHori, ‡§ IanE.Alexander, DavidC.H.Harris, † and StephenI.Alexander* *CentreforKidneyResearchand GeneTherapyResearchUnit,Childr...
There was no benefit of muromonab-CD3 over ATG or ALG in either reversing rejection, preventing subsequent rejection, preventing graft loss or death. In reversing first rejection, any antibody is better than steroid and also prevents graft loss, but subsequent rejection and patient survival are not...
At intervals of 6 months, the following parameters were measured prospectively: lymphocyte surface antigens (HLA-DR, CD3, CD4, CD8, CD16, CD19, CD56, and CD57); serum and urine neopterin; serum amyloid A; and indirect and direct tests for herpes viruses. Results. The mean period ...
As single-CD28 stimulation led to limited expansion rates, we examined a CD28-superagonist antibody and demonstrate a significant increased Treg expansion that was more efficient than standard anti-CD3/CD28-bead stimulation. CD28-superagonist stimulation drove both nave and memory Treg proliferation. ...